...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>ANZ journal of surgery >Uptake of adjuvant breast cancer treatments recommended by multi‐disciplinary meetings
【24h】

Uptake of adjuvant breast cancer treatments recommended by multi‐disciplinary meetings

机译：多学科会议推荐的佐剂乳腺癌治疗的吸收

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Adjuvant therapy for breast cancer is routinely discussed and recommended in multi‐disciplinary meetings (MDMs). Current literature explores how treatments received by patients differ from national guidelines; however, it does not explore whether treatment is concordant with MDMs. This study provides an Australian perspective on the uptake of MDM recommendations and reasons for non‐concordance. Methods A retrospective cohort study of patients with breast cancer presented at The Royal Melbourne Hospital MDM in 2010 and 2014 to investigate the concordance between MDM recommendations and treatment received. Results The study group comprised 441 patients (161 from 2010 and 280 from 2014). A total of 375 patients were included in the analyses. Overall, 82% of patients had perfect concordance between recommended and received treatment for all modes of adjuvant therapy. Concordance to endocrine therapy was higher for invasive cancers than ductal carcinoma in situ (97% versus 81%, P 0.0001). Concordance to radiotherapy was high and did not differ according to type of cancer or surgery (ranging from 88 to 91%). Concordance to chemotherapy recommendations was high overall (92%) and did not vary with nodal status. Women aged over 65 years were least likely to be recommended for adjuvant therapy but most likely to concordant with the recommendation. Conclusions Uptake of MDM‐recommended treatments is high. There is a minority of patients in whom MDM recommendations are not followed, highlighting that there are extra steps between recommendations at an MDM and decisions with patients. More attention to this issue is appropriate, and the reasons for non‐concordance warrant further study.
机译：背景技术乳腺癌的佐剂治疗是经常讨论的，并推荐在多学科会议（MDMS）中。目前的文献探讨了患者接受的治疗如何与国家指导方针不同;然而，它不会探索治疗是否协调mdms。本研究提供了澳大利亚对MDM建议的影响和非协调理由的观点。方法对2010年至2014年皇家墨尔本医院MDM患者患有乳腺癌患者的回顾性队列研究，探讨了MDM建议和治疗的一致性。结果研究组由441名患者（2014年从2010年和280名161名）组成。分析中共有375名患者。总体而言，82％的患者在推荐和接受治疗的所有辅助治疗模式之间具有完美的一致性。对内分泌治疗的一致性对侵入性癌症的一致性比导管癌原位（97％对81％，P＆ 0.0001）。放射疗法的一致性高，根据癌症或手术的类型没有差异（从88到91％的范围）。对化疗建议的一致性高总体（92％），并且没有因节点状态而变化。超过65岁以上的女性最不可能推荐用于佐剂治疗，但最有可能协调一致。结论吸收MDM推荐的治疗方法很高。没有少数少数患者，没有遵循MDM建议，突出显示MDM的建议与患者的决定之间存在额外的步骤。更加关注这个问题是合适的，并且不一致的原因需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号